Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amicus Therapeutics

5.84
+0.11001.92%
Post-market: 5.83-0.0100-0.17%19:22 EDT
Volume:5.18M
Turnover:30.28M
Market Cap:1.80B
PE:-60.76
High:5.99
Open:5.70
Low:5.66
Close:5.73
Loading ...

Amicus announces approval of Pombiliti + Opfolda in Japan

TIPRANKS
·
25 Jun

BRIEF-Amicus Therapeutics Announces Approval Of Pombiliti®

Reuters
·
25 Jun

Amicus Therapeutics Announces Approval of Pombiliti® (Cipaglucosidase Alfa) + Opfolda® (Miglustat) in Japan

THOMSON REUTERS
·
25 Jun

Amicus Therapeutics Inc. Conducted Annual Stockholder Meeting

Reuters
·
06 Jun

Top Research Reports for Meta Platforms, Broadcom & JPMorgan

Zacks
·
04 Jun

FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls

Zacks
·
03 May

Amicus Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
03 May

Amicus price target raised to $22 from $21 at UBS

TIPRANKS
·
02 May

UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating

MT Newswires Live
·
02 May

Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today

MotleyFool
·
02 May

Amicus Therapeutics’ Earnings Call Highlights Growth and Strategic Moves

TIPRANKS
·
02 May

Amicus Therapeutics Down Over 12%, on Pace for Largest Percent Decrease Since January 2022 -- Data Talk

Dow Jones
·
02 May

Amicus (FOLD) Gets a Hold from Needham

TIPRANKS
·
02 May

Amicus Therapeutics Turns to Non-GAAP Q1 Earnings, Revenue Rises; Shares Down

MT Newswires Live
·
01 May

Amicus Therapeutics Shares Down 3.7% Premarket After Q1 REV Miss

THOMSON REUTERS
·
01 May

Earnings Flash (FOLD) Amicus Therapeutics Posts Q1 Revenue $125.2M, vs. FactSet Est of $135.9M

MT Newswires Live
·
01 May

Amicus Therapeutics: Q1 Earnings Snapshot

Associated Press Finance
·
01 May

Amicus reports Q1 non-GAAP EPS 3c, consensus 8c

TIPRANKS
·
01 May

BRIEF-Amicus Therapeutics Q1 Revenue USD 125.2 Million Vs. IBES Estimate USD 135.9 Million

Reuters
·
01 May

Amicus Therapeutics Inc Outlook FY25 Total Revenue Growth 15% to 22%

THOMSON REUTERS
·
01 May